Article Case No. No. of SGBs Anesthetic Type & Dosage Instrument1 PTSD Severity Pre-SGB (1,2,3)2 PTSD Severity Post-SGB (1,2,3)2 Overall Improvement in PTSD (%)2,4 Follow-up Time (1,2,3)2 Mulvaney et al. [51] 1 2 Ropivacaine (7cc, 0.5% soln) PCL-M 76, 67 26, 34 71.2* 1 day, 264 days 2 1 Ropivacaine (7cc, 0.5% soln) PCL-M 54 24 81.1* 50 days Hickey et al. [52] 3 1 Ropivacaine (7cc, 0.5% soln) CAPS 126 118 6.3 7 days 4 1 Ropivacaine (7cc, 0.5% soln) CAPS 87 60 31.0* 7 days 5 1 Ropivacaine (7cc, 0.5% soln) CAPS 83 56 32.5* 6 days 6 2 Ropivacaine (7cc, 0.5% soln) CAPS 106, 79 26, 18 83.0* 9 days, 103 days 7 1 Ropivacaine (7cc, 0.5% soln) CAPS 117 79 32.5* 7 days 8 1 Ropivacaine (7cc, 0.5% soln) CAPS 64 52 18.8 7 days 9 1 Ropivacaine (7cc, 0.5% soln) CAPS 104 43 58.7* 7 days Article Case No. No. of SGBs Anesthetic Type & Dosage Instrument1 PTSD Severity Pre-SGB (1,2,3)2 PTSD Severity Post-SGB (1,2,3)2 Overall Improvement in PTSD (%)2,4 Follow-up Time (1,2,3)2   10 2 Ropivacaine (7cc, 0.5% soln) CAPS3 104, - 103, 96 7.7 7 days, 28 days   11 1 Ropivacaine (7cc, 0.5% soln) CAPS 101 79 21.8 7 days Lipov et al. [53] 12 1 Bupivicaine (7cc, 0.5% soln) PCL-M 58 51 17.1 16 days 13 1 Bupivicaine (7cc, 0.5% soln) PCL-M 68 35 64.7* 3 days 14 1 Bupivicaine (7cc, 0.5% soln) PCL-M 67 63 8.0 1 day 15 1 Bupivicaine (7cc, 0.5% soln) PCL-M 68 31 72.5* 48 days 16 1 Bupivicaine (7cc, 0.5% soln) PCL-M 55 29 68.4* 4 days 17 1 Bupivicaine (7cc, 0.5% soln) PCL-M 77 23 90.0* 6 days 18 2 Bupivicaine (7cc, 0.5% soln) PCL-M 70, 70 17, 29 77.4* 1 day, 2 days Article Case No. No. of SGBs Anesthetic Type & Dosage Instrument1 PTSD Severity Pre-SGB (1,2,3)2 PTSD Severity Post-SGB (1,2,3)2 Overall Improvement in PTSD (%)2,4 Follow-up Time (1,2,3)2   19 3 Bupivicaine (7cc, 0.5% soln) PCL-M3 79, -, 30 54, -, 21 93.5* 1 day, 17 days, 59 days Lipov et al. [54] 20 2 Bupivicaine (6.5cc, 0.5% soln) PCL-M 71, 66 40, 30 75.9* 43 days, 135 days Alino et al. [55] 21 2 Ropivacaine (7cc, 0.5% soln) PCL-M 64, 35 22, 29 74.5* 3 days, 136 days   22 1 Ropivacaine (7cc, 0.5% soln) PCL-M 80 18 98.4* 2 days 23 1 Ropivacaine (7cc, 0.5% soln) PCL-M 69 34 67.3* 30 days 24 1 Ropivacaine (7cc, 0.5% soln) PCL-M 76 24 88.1* 1 day *Clinically meaningful improvement in PTSD-related symptoms with ≥ 30% decline in PCL or CAPS scores. For cases with 1 SGB treatment, overall improvement was calculated using the pre-SGB 1 and post-SGB 1 scores. For cases with 2 SGB treatments, overall improvement was calculated using the pre-SGB 1 and post-SGB 2 or 3 scores. 1PCL=Post-Traumatic Stress Disorder Checklist - Military Version, CAPS=Clinician-Administered Post-Traumatic Stress Disorder Scale. 2Post-traumatic stress disorder symptom severity pre- or post-SGB treatments 1, 2 or 3 as applicable; Follow-up time was computed from SGB 1 to the last point of contact with patient when PCL or CAPS assessments were collected. 3Some data were missing. 4Overall Improvements calculated as the difference in either PCL-M or CAPS scores from pre-SGB 1 to post-SGB 2 or 3. PTSD improvement as measured by the PCL-M were adjusted by subtracting 17 from all pre- and post-SGB scores given the baseline value of PCL-M starts at 17, not 0 as is the case for CAPS.

Table 2: Comparative Summary of Stellate Ganglion Block Treatments and Overall Improvement in Post-Traumatic Stress Disorder